bih.button.backtotop.text
BROWSE BY TEST NAME
%
1
2
3
5
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
Clear
 
Test Code:
CDAA

Order Name:
Celiac Profile

 
Useful For:
Diagnosis of celiac disease in the suspected patient.
 
Methodology:
Enzyme-linked Immunosorbent Assay (ELISA)
 
Test List In Profile:
Deamidated Gliadin Peptide (DGP) antibody, IgA
Deamidated Gliadin Peptide (DGP) antibody, IgG
Anti-tissue Transglutaminase IgA
Anti-tissue Transglutaminase IgG
 
AliasesName:
Celiac Disease
Coeliac Disease
Dermatitis Herpetiformis
Gliadin Antibodies IgA
Gliadin Antibodies IgG
Gliadin IgA, Serum
Gliadin IgG, Serum
Gluten-sensitive Enteropathy
Sprue
Tissue Transglutaminase (tTG)
Tissue Transglutaminase Ab IgA
Transglutaminase (tTG)
Deamidated Gliadin Peptide (DGP) antibody
 
 
 
Test Code:
CDAA

Order Name:
Celiac Profile

 
Collection Specimen Or Container:
Blood/ Plain blood (Red top) 6 mL, 1 tube
 
Specimen Testing Type:
Serum, minimum volume 0.5 mL
 
Sub Mission Container:
Plastic tube
 
Rejection Criteria:
Hemolysis: Mild OK; Gross reject
Lipemia: Mild OK; Gross reject
Icterus: Mild OK; Gross reject
 
Specimen Stabillity:
Specimen Type Temperature Time
Serum Refrigerated, 2oC to 8oC 14 days
 
 
 
Test Code:
CDAA

Order Name:
Celiac Profile

 
Method detail:
Enzyme-linked Immunosorbent Assay (ELISA)
 
Schedule:
Test daily, at 01:00 p.m.
 
Turnaround Time:
Received specimen to reported within 2 days.
 
Performing Location:
Molecular biology & Genetics, Laboratory Department Tel.14168
 
Specimen Retention Time:
7 days
 
 
 
Test Code:
CDAA

Order Name:
Celiac Profile

 
 
Clinical Information:
The highly sensitive tests Anti-Gliadin (GAF-3X) ELISA serve for the determination of the celiac disease related fraction of gliadin antibodies in the serological diagnosis of gluten-sensitive enteropathy (celiac disease, non-tropical sprue) and Duhring’s dermatitis herpetiformis. Celiac disease is an autoimmune disease which occurs in predisposed individuals as a reaction to gluten sensitivity. After absorption in the lamina propria of the intestinal mucosa gliadin is deamidated by tissue transglutaminase (tTG). In this process particular glutamine residues are replaced by glutamic acid residues. In individuals with a genetic predisposition pieces (peptides) of gliadin modified (reconstructed) in this way bind to e.g. HLADQ2/8 molecules of the antigen presenting cells and are presented to helper T cells. An extensive immune reaction is triggered, causing pathological tissue changes, particularly damage to the small intestine. Components of this immune reaction are antibodies against endomysium or tTG and against the deamidated gliadin generated by tTG. The frequency of diagnosed coeliac disease amounts to around 1:300 in western Ireland, Italy, the USA, the Middle East, India and Cuba, around 1:1,000 in Germany and Austria and around 1:2,000 to 1:4,500 in other European countries. The clinical symptoms comprise fatigue (78%), borborygmus (72%), abdominal pain (64%), diarrhoea (56%), effects of malabsorption (44%) with weight loss, anaemia and growth retardation in children, vomiting (16%), constipation (12%) and bone pains (12%). Some patients with glutensensitive enteropathy also suffer from Duhring's dermatitis herpetiformis (10%), a chronic skin disease accompanied by the formation of blisters. In a prolonged course, mainly in adults, the risk of melanoma, particularly intestinal T-cell lymphoma, is about 10%
 
Reference Value:
Test Reference Value Unit
Deamidated Gliadin Peptide (DGP) antibody, IgA <25 RU/mL
Deamidated Gliadin Peptide (DGP) antibody, IgG <25 RU/mL
Anti-tissue Transglutaminase IgA <20 RU/mL
Anti-tissue Transglutaminase IgG Negative -
 
Interpretation:
See details from individual unit test.
 
Clinical Reference:
See details from individual unit test.